Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07270601 · ClinicalTrials.gov registry record · NA

Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

A NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and NAFLD - Non-Alcoholic Fatty Liver Disease, sponsored by ContextVision AB.

Recruiting
Registry status
NA
Development phase
110
Enrollment target
1
Study location

NCT07270601 is a NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and NAFLD - Non-Alcoholic Fatty Liver Disease that is actively recruiting participants, run by ContextVision AB. The registered enrollment target is 110 participants, above the 83-participant average among 5 other MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07270601, a NA study of MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease and NAFLD - Non-Alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by ContextVision AB.

RECRUITING
Registry status
NA
Development phase
110 participants
Enrollment target
1
Study location

Study Summary

The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way to monitor liver health - especially for people with obesity, diabetes, high blood pressure, or high cholesterol.

Conditions Studied

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease NAFLD - Non-Alcoholic Fatty Liver Disease

Interventions

  • DEVICE Verasonics NXT Data Acquisition System
  • DEVICE Philips EPIQ Elite
  • DEVICE EchoSense FibroScan
  • DEVICE Philips 3T Ingenia Elition

Study Locations (1)

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2025-11-17
Est. Completion 2026-12-31
Phase NA

Sponsor

ContextVision AB

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07270601

The ClinicalTrials.gov registry entry for NCT07270601 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 5 other MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease trials with a reported enrollment target (33% higher). The listed sponsor is ContextVision AB, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease appearing as the primary indexed condition, and to 4 interventions - of which Verasonics NXT Data Acquisition System is the first listed.

NCT07270601 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT07270601 about?

NCT07270601 is a clinical study titled "Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis". The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expens...

What is the current status of trial NCT07270601?

This trial is currently recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2025-11-17. Estimated completion is 2026-12-31.

What conditions does trial NCT07270601 study?

This clinical trial studies the following conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease.

What interventions are being tested in trial NCT07270601?

The interventions under investigation include: Verasonics NXT Data Acquisition System (DEVICE), Philips EPIQ Elite (DEVICE), EchoSense FibroScan (DEVICE), Philips 3T Ingenia Elition (DEVICE).

Who is sponsoring clinical trial NCT07270601?

This trial is sponsored by ContextVision AB, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07270601 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease

All registered trials for this condition

NAFLD - Non-Alcoholic Fatty Liver Disease

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.